Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 176Colorectal Neoplasms 153Rectal Neoplasms 122Stomach Neoplasms 112Pancreatic Neoplasms 60Neoplasm Metastasis 60Colonic Neoplasms 42Triple Negative Breast Neoplasms 34Neoplasms 29Esophageal Neoplasms 28Cholangiocarcinoma 17Biliary Tract Neoplasms 17Nasopharyngeal Carcinoma 16Gallbladder Neoplasms 16Carcinoma, Hepatocellular 16Adenocarcinoma 16Locally Advanced Rectal Cancer 15Squamous Cell Carcinoma of Head and Neck 10Head and Neck Neoplasms 10Esophageal Squamous Cell Carcinoma 10Brain Neoplasms 10Bile Duct Neoplasms 10Adenocarcinoma Of Esophagus 10Liver Neoplasms 9Gastrointestinal Neoplasms 9Breast Neoplasms, Male 9Neuroendocrine Tumors 7Colorectal Cancer Metastatic 7Carcinoma, Renal Cell 7Ovarian Neoplasms 6

Interventions

blinatumomab 9Cyclophosphamide 7Rituximab 6Lenalidomide 6Dexamethasone 5Azacitidine 5venetoclax 4fludarabine 4Cytarabine 4fludarabine phosphate 3Maintenance 3Busulfan 3tislelizumab 2thymoglobulin 2pembrolizumab 2obinutuzumab 2daratumumab 2Whole-Body Irradiation 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Methotrexate 2Melphalan 2Immunotherapy 2Imatinib Mesylate 2Drug Therapy 2Docetaxel 2Decitabine 2Clofarabine 2Cladribine 2Carboplatin 2Calcium Dobesilate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm, Residual × Capecitabine × Clear all
NCT04768426 2026-04-13

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Stanford University

Phase 2 Recruiting
40 enrolled
Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡